Login to Your Account

Clinic Roundup

Monday, November 7, 2011

• Galena Biopharma Inc., of Lake Oswego, Ore., reported that data from Phase II clinical trials of its NeuVax vaccine showed that it may provide a meaningful clinical benefit in patients with less aggressive forms of breast cancer, and potentially keep them free of their disease. Results were presented at the 26th Annual Meeting of the Society for the Immunotherapy of Cancer in North Bethesda, Md.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription